Industry
Biotechnology
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Loading...
Open
48.29
Mkt cap
3B
Volume
600K
High
48.88
P/E Ratio
-21.96
52-wk high
50.78
Low
47.10
Div yield
N/A
52-wk low
11.69
Portfolio Pulse from Benzinga Newsdesk
October 16, 2024 | 2:42 pm
Portfolio Pulse from Benzinga Newsdesk
October 03, 2024 | 2:59 pm
Portfolio Pulse from Benzinga Newsdesk
October 02, 2024 | 10:33 am
Portfolio Pulse from Benzinga Newsdesk
October 02, 2024 | 10:32 am
Portfolio Pulse from Benzinga Newsdesk
October 01, 2024 | 12:16 pm
Portfolio Pulse from Benzinga Newsdesk
September 23, 2024 | 12:46 pm
Portfolio Pulse from Benzinga Newsdesk
September 16, 2024 | 5:05 pm
Portfolio Pulse from Benzinga Newsdesk
September 16, 2024 | 2:16 pm
Portfolio Pulse from Benzinga Newsdesk
September 16, 2024 | 12:06 pm
Portfolio Pulse from Benzinga Newsdesk
September 12, 2024 | 12:01 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.